These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22222184)

  • 1. Functionalized carriers for the improved delivery of plasminogen activators.
    Vaidya B; Agrawal GP; Vyas SP
    Int J Pharm; 2012 Mar; 424(1-2):1-11. PubMed ID: 22222184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activators: a comparison.
    Baruah DB; Dash RN; Chaudhari MR; Kadam SS
    Vascul Pharmacol; 2006 Jan; 44(1):1-9. PubMed ID: 16275118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered microparticles and nanoparticles for fibrinolysis.
    Disharoon D; Marr DWM; Neeves KB
    J Thromb Haemost; 2019 Dec; 17(12):2004-2015. PubMed ID: 31529593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
    Hagemeyer CE; Tomic I; Weirich U; Graeber J; Nordt T; Runge MS; Bode C; Peter K
    J Thromb Haemost; 2004 May; 2(5):797-803. PubMed ID: 15099287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regimens for administering plasminogen activators].
    Maksimenko AV
    Eksp Klin Farmakol; 1996; 59(4):58-64. PubMed ID: 9026195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The fibrinolytic system and its activators].
    Seifried E
    Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
    Gurewich V
    Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
    [No Abstract]   [Full Text] [Related]  

  • 9. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of a platelet-targeted plasminogen activator with enhanced thrombolytic and antithrombotic potency.
    Yan HL; Sun SH; Wang WT; Ding FX; Mei Q; Xue G
    Biotechnol Appl Biochem; 2007 Feb; 46(Pt 2):115-25. PubMed ID: 16965265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 12. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
    Bell WR
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic agents--an overview.
    Gulba DC; Bode C; Runge MS; Huber K
    Ann Hematol; 1996; 73 Suppl 1():S9-27. PubMed ID: 8853112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should intravenous thrombolytic agents for acute myocardial infarction be selected?
    Topol EJ
    Cardiovasc Clin; 1990; 21(1):57-75; discussion 76-8. PubMed ID: 2143103
    [No Abstract]   [Full Text] [Related]  

  • 16. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte- and fibrin-content of a thrombus?].
    Kirchhof K; Sikinger M; Welzel T; Zoubaa S; Sartor K
    Rofo; 2004 Jan; 176(1):98-105. PubMed ID: 14712413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term benefit of one thrombolytic over another.
    Grobman BJ
    Circulation; 1997 Sep; 96(6):2093. PubMed ID: 9323115
    [No Abstract]   [Full Text] [Related]  

  • 20. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.